Piribo, (http://www.piribo.com) the online destination for business intelligence for the biotech and pharmaceutical industry, has added a key report discussing the PROactive trial results
and the current and future prevalence of diabetes.
The socio-economic consequences of diabetes and its complications make it a major public health issue. Patients with diabetes have a 25% reduction in life expectancy compared with the
general population, mainly due to cardiovascular deaths.
"PROactive Results -The Diabetes Trial That Could Have Been" evaluates the current and future prevalence of diabetes in the seven major markets, discusses the rationale and study design
of the PROactive trial, presents the cardiovascular and metabolic results of the PROactive trial, and provides an independent commentary and discussion of the likely impact of the study
on future prescribing trends.
The report highlights that the drivers for growth in the diabetic patient population include the aging demographic profile and the explosion in obesity rates. While the evidence for
growth in type 1 diabetes is equivocal, the overwhelming majority of the diabetic population suffers from type 2 and the characteristics of this segment will dictate future growth
patterns.
Read this report to gain an independent view on the results of one of the most important diabetic trials to date, examine the reasons driving the need for outcome trials such as
PROactive, and assess the metabolic and cardiovascular results of the PROactive trial.
"PROactive Results -The Diabetes Trial That Could Have Been" is priced at £2195 and is available to download in PDF format or to receive as a hardcopy for £2225 from Piribo. For more
information go to:
http://www.piribo.com/publications/diseases_conditions/diabetes/DAT384.html